BioAge Labs at Morgan Stanley conference: BGE-102 gains focus
On 16 September 2026, BioAge Labs (BIOA) showcased its strategy centered on aging biology, inflammation, and novel disease targets during its presentation at the Morgan Stanley 24th Annual Global Healthcare Conference. The biotech company highlighted promising early data for its lead drug BGE-102, while acknowledging a setback in the cardiovascular inflammation field and a pause in a planned late-stage study.
BioAge sees opportunities in its platform and BGE-102, but is adopting a more selective approach following a recent trial failure in a competing pathway. The stock of BioAge Labs has fallen 62% over the past six months, trading at $8.02, despite a 67% gain over the past year. BioAge holds more cash than debt on its balance sheet, providing a financial cushion for a clinical-stage biotech company.
The company's lead program, BGE-102, demonstrated strong Phase I results, with 86% reductions in hsCRP and high target coverage at tested doses. Two Phase II studies are currently underway: QUELL-CV, targeting obese patients with inflammation, and QUELL-DME, focusing on diabetic macular edema. BioAge is also exploring APJ agonists as a long-term program to improve weight-loss outcomes alongside GLP-1 drugs.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
